Skip to Main Content
Table 1—

Changes in major and emerging CVD risk factors during and between the Salba and control treatments (n = 20)

Salba
Control
Between treatment
Week 0Week 12Change (%)Week 0Week 12Change (%)Change (%)P value
Major CVD risk factors         
    A1C (%) 6.9 ± 0.8 6.7 ± 0.9 −2.9 ± 8.4* 6.7 ± 0.8 6.7 ± 0.9 −0.2 ± 6.7 −2.6 ± 12.4 0.37 
    Fasting blood glucose (mmol/l) 7.4 ± 2.1 7.2 ± 1.9 −0.7 ± 21.7 7.1 ± 1.5 7.6 ± 1.9 4.1 ± 11.6 −7.3 ± 25.5 0.12 
    Fasting blood insulin (pmol/l) 74.4 ± 28.8 86.1 ± 39.1 17.5 ± 34.7 82.2 ± 35.6 85.1 ± 44.4 3.5 ± 25.2 14.0 ± 43.2 0.24 
    Total cholesterol (mmol/l) 5.1 ± 1.2 4.9 ± 1.2 −2.3 ± 1.2 5.0 ± 1.2 5.0 ± 1.2 0.5 ± 1.2 −2.8 ± 0.6 0.47 
    LDL cholesterol (mmol/l) 3.0 ± 1.0 3.0 ± 1.0 −1.2 ± 1.0 2.9 ± 0.9 3.0 ± 1.0 2.0 ± 1.0 −3.2 ± 0.4 0.56 
    HDL cholesterol (mmol/l) 1.3 ± 0.2 1.2 ± 0.3 −5.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.2 −1.5 ± 0.3 −3.7 ± 0.1 0.26 
    Triglycerides (mmol/l) 1.6 ± 0.8 1.6 ± 0.8 −1.7 ± 0.8 1.7 ± 0.9 1.7 ± 0.8 −2.1 ± 0.8 0.4 ± 0.4 0.95 
    SBP (mmHg) 129 ± 17 123 ± 16 −9.5 ± 1* 122 ± 15 129 ± 17 10 ± 2* −20 ± 1 >0.01 
    DBP (mmHg) 81 ± 9 78 ± 8 −3 ± 1.3 76 ± 9 79 ± 7 9.2 ± 1.3* −7 ± 1 >0.05 
Emerging CVD risk factors         
    hs-CRP (mg/l) 3.1 ± 2.4 2.9 ± 2.3 −7.0 ± 2.3 2.6 ± 2.1 3.4 ± 2.3 32.9 ± 2.2* −39.9 ± 1.6 0.04 
    Fibrinogen (g/l) 3.52 ± 0.76 3.37 ± 0.61 −5.32 ± 0.68* 3.24 ± 0.69 3.35 ± 0.71 3.57 ± 0.69 −8.89 ± 0.52 0.1 
    vWF 1.14 ± 0.38 1.038 ± 0.45 −9.12 ± 0.41 1.158 ± 0.66 1.299 ± 0.61 12.13 ± 0.63 −21.25 ± 0.34 0.03 
    Factor VIII 1.04 ± 0.36 0.95 ± 0.36 −8.68 ± 0.36 0.85 ± 0.39 0.97 ± 0.47 14.3 ± 0.43 −22.98 ± 0.29 0.06 
Salba
Control
Between treatment
Week 0Week 12Change (%)Week 0Week 12Change (%)Change (%)P value
Major CVD risk factors         
    A1C (%) 6.9 ± 0.8 6.7 ± 0.9 −2.9 ± 8.4* 6.7 ± 0.8 6.7 ± 0.9 −0.2 ± 6.7 −2.6 ± 12.4 0.37 
    Fasting blood glucose (mmol/l) 7.4 ± 2.1 7.2 ± 1.9 −0.7 ± 21.7 7.1 ± 1.5 7.6 ± 1.9 4.1 ± 11.6 −7.3 ± 25.5 0.12 
    Fasting blood insulin (pmol/l) 74.4 ± 28.8 86.1 ± 39.1 17.5 ± 34.7 82.2 ± 35.6 85.1 ± 44.4 3.5 ± 25.2 14.0 ± 43.2 0.24 
    Total cholesterol (mmol/l) 5.1 ± 1.2 4.9 ± 1.2 −2.3 ± 1.2 5.0 ± 1.2 5.0 ± 1.2 0.5 ± 1.2 −2.8 ± 0.6 0.47 
    LDL cholesterol (mmol/l) 3.0 ± 1.0 3.0 ± 1.0 −1.2 ± 1.0 2.9 ± 0.9 3.0 ± 1.0 2.0 ± 1.0 −3.2 ± 0.4 0.56 
    HDL cholesterol (mmol/l) 1.3 ± 0.2 1.2 ± 0.3 −5.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.2 −1.5 ± 0.3 −3.7 ± 0.1 0.26 
    Triglycerides (mmol/l) 1.6 ± 0.8 1.6 ± 0.8 −1.7 ± 0.8 1.7 ± 0.9 1.7 ± 0.8 −2.1 ± 0.8 0.4 ± 0.4 0.95 
    SBP (mmHg) 129 ± 17 123 ± 16 −9.5 ± 1* 122 ± 15 129 ± 17 10 ± 2* −20 ± 1 >0.01 
    DBP (mmHg) 81 ± 9 78 ± 8 −3 ± 1.3 76 ± 9 79 ± 7 9.2 ± 1.3* −7 ± 1 >0.05 
Emerging CVD risk factors         
    hs-CRP (mg/l) 3.1 ± 2.4 2.9 ± 2.3 −7.0 ± 2.3 2.6 ± 2.1 3.4 ± 2.3 32.9 ± 2.2* −39.9 ± 1.6 0.04 
    Fibrinogen (g/l) 3.52 ± 0.76 3.37 ± 0.61 −5.32 ± 0.68* 3.24 ± 0.69 3.35 ± 0.71 3.57 ± 0.69 −8.89 ± 0.52 0.1 
    vWF 1.14 ± 0.38 1.038 ± 0.45 −9.12 ± 0.41 1.158 ± 0.66 1.299 ± 0.61 12.13 ± 0.63 −21.25 ± 0.34 0.03 
    Factor VIII 1.04 ± 0.36 0.95 ± 0.36 −8.68 ± 0.36 0.85 ± 0.39 0.97 ± 0.47 14.3 ± 0.43 −22.98 ± 0.29 0.06 

Data are means ± SD and represent measures of efficacy. The safety and compliance data are described in the text. P values refer to between-treatment differences using repeated-measures general linear model ANOVA adjusted for age, sex, weight, antihyperglycemic agents (A1C, fasting blood glucose, and fasting blood insulin); for age, sex, weight, BMI, lipid-lowering medications (total, LDL, and HDL cholesterol; triglycerides; and hs-CRP); for age, sex, weight, and aspirin use (fibrinogen, vWF, and factor VIII); and for age, sex, weight, and blood pressure medications (SBP and DBP). Percent changes for each variable are based on the calculation for each individual subject’s percent change.

*

P < 0.05.

Close Modal

or Create an Account

Close Modal
Close Modal